KVUE Stock Analysis — Kenvue
Sector: Consumer staples
AI Verdict
KVUE trades at a bargain price for expected growth, but the market is skeptical that its brand moat will translate into the forecasted earnings rebound.
Competitive Moat
Kenvue owns household brands like Tylenol, Band-Aid, and Listerine, giving it a durable shelf-space and consumer trust advantage in over-the-counter health products. Its scale and entrenched distribution relationships with major retailers make it hard for new entrants to displace its products.
Summary
Kenvue is trading at a steep discount to its sector despite a sharp expected rebound in earnings.
Where It Stands
KVUE is down -26.13% over the past year, trades at 15.0x next year's earnings versus the sector median of 20x, and its RSI of 53.9 signals a neutral setup.
Key Metrics
- RSI: 53.9 — Neutral
- Trailing P/E: 20.8x
- Forward P/E: 15.0x
- PEG Ratio: 0.54
- Earnings Growth: +0.4%
- Revenue Growth: -0.0%
- Market Cap: $33.7B
- Dividend Yield: 0.05%
- 1-Year Return: -26.13%
- 52-Week High: $24.03
- 52-Week Low: $14.02
Analyst Consensus
1 Buy · 15 Hold · 4 Sell (20 analysts)
Bull Case
Analysts expect 38.7% EPS growth next year while the stock trades at just 15.0x forward earnings, making it cheap for the growth you're getting.
Bear Case
If the forward P/E reverts to the sector median of 20x after a weak quarter, the stock could see a sharp rerating, but if growth disappoints, the current discount could persist or widen.
Catalyst to Watch
Watch for quarterly earnings to confirm the expected 38.7% EPS rebound, as any miss could undermine the case for multiple expansion.